0001209191-20-044098.txt : 20200730
0001209191-20-044098.hdr.sgml : 20200730
20200730194852
ACCESSION NUMBER: 0001209191-20-044098
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200728
FILED AS OF DATE: 20200730
DATE AS OF CHANGE: 20200730
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rosenberg Noah L.
CENTRAL INDEX KEY: 0001579649
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 201062408
MAIL ADDRESS:
STREET 1: C/O ESPERION THERAPEUTICS, INC.
STREET 2: 46701 COMMERCE CENTER DRIVE
CITY: PLYMOUTH
STATE: MI
ZIP: 48170
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Retrophin, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3721 VALLEY CENTRE DR.
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 760-260-8600
MAIL ADDRESS:
STREET 1: 3721 VALLEY CENTRE DR.
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-28
0
0001438533
Retrophin, Inc.
RTRX
0001579649
Rosenberg Noah L.
C/O RETROPHIN, INC.
3721 VALLEY CENTRE DRIVE, SUITE 200
SAN DIEGO
CA
92130
0
1
0
0
Chief Medical Officer
Common Stock
2020-07-28
4
S
0
870
20.49
D
26055
D
Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
Includes 197 shares of the Issuer's common stock acquired by the reporting person on May 31, 2020 pursuant to an employee stock purchase program.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2020-07-30